Visão geral da empresa
A biotechnology firm, Inovio Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of DNA medicines designed to treat and protect individuals from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, which implies a focus on high-risk research and development phases rather than mature manufacturing cycles. Inovio currently maintains a market capitalization of $85.67M, generates annual revenue of $65,343, and employs 112 individuals. These valuation and revenue figures indicate that the company is a micro-cap entity operating with a very small financial footprint relative to the broader biotechnology market. The minimal revenue generation combined with a market cap under $100 million suggests the firm is still in a critical early-stage phase where capital preservation is prioritized over revenue expansion.
Saúde financeira
The company reported a revenue of $65,343 over the trailing twelve months, yet recorded a net income of -$84,945,904, revealing a cost structure where expenses far exceed any generated income. The EBITDA stands at -$85,404,192, further confirming that the business model currently generates negative operating cash flow before financing costs. Free cash flow is reported at -$38,681,548, indicating a significant outflow of cash that limits the company's immediate financial flexibility and reliance on external capital injections. Analysis of the three margins shows a gross margin of 0.0%, an operating margin of -132871.3%, and a profit margin of 0.0%, which collectively indicate severe inefficiency in converting sales into profit and substantial overhead costs relative to the tiny revenue base. The balance sheet holds $58.51M in cash against $9.37M in debt, creating a net cash position, while the debt-to-equity ratio is 38.88, suggesting a leveraged structure despite the lack of interest-bearing debt burden relative to equity. The current ratio is 1.40, indicating that the company possesses 1.40 dollars in current assets for every dollar of current liabilities, which points to adequate short-term liquidity to meet immediate obligations. Return on Equity is -183.5% and Return on Assets is -57.9%, revealing that management is currently destroying shareholder value and utilizing assets inefficiently due to the heavy burning of cash reserves.
Avaliação de valorização
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -1.62, implying that the market expects the company to return to profitability or that valuation models are relying on non-GAAP adjustments for this loss-making stage. The price-to-book ratio is 3.01, indicating that the market values the company at more than three times its net asset value, which is a significant premium for a firm with negative earnings and minimal revenue. The price-to-sales ratio is 1311.11 and the EV/EBITDA is -0.27, suggesting that traditional valuation multiples are distorted by the company's lack of profitability and that investors are pricing in future clinical success or regulatory approvals rather than current financial performance. The 52-week high is $2.98 and the 52-week low is $1.05, meaning the stock trades at a premium above its yearly minimum but remains well below its peak valuation observed in the last year. The beta value is 1.70, which means the stock exhibits 70% higher volatility than the broader market, reflecting the high risk profile associated with small-cap biotechnology companies dependent on specific asset milestones.
Growth & Income
Revenue growth year-over-year is -100.0%, while earnings growth is N/A, indicating a complete contraction in top-line sales and the absence of a profitable earnings history to measure growth trajectories. Since the revenue has collapsed to near zero, there is no growth comparison possible between earnings and revenue, but the absolute loss confirms a failure to generate commercial traction in the current period. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all available capital and reinvests earnings—or rather, burns cash—into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue momentum and a total absence of dividend income, positioning the stock purely as a speculative vehicle dependent on future clinical outcomes rather than current financial stability or shareholder returns.